---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-035298"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2024-09-06T23:59:59+00:00"
generated_at: "2026-05-31T06:06:59.865108+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PowerUp Acquisition Corp. amends Aspire Biopharma merger; consideration set at $350M

## Summary
- Merger consideration adjusted to $350M less cash shortfall and debt, reflecting anticipated ownership percentages.
- Equity incentive plan pool set at greater of 10% of post-closing shares or 5M shares, with annual evergreen provision.
- Disclosure schedule delivery date extended to September 18, 2024, with 7-day review and cure period.
- Amendment signed September 5, 2024, provides additional time for due diligence and disclosure schedules.
- Deal remains subject to shareholder approvals and Nasdaq listing standards.

## SEC filing metadata
- accession: 0001493152-24-035298
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2024-09-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315224035298/0001493152-24-035298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315224035298/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-035298
- JSON: https://secwatch.observer/filing/0001493152-24-035298.json
- Plain text: https://secwatch.observer/filing/0001493152-24-035298.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.